Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel
|
|
- Edwina Welch
- 6 years ago
- Views:
Transcription
1 Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel Karsten Schrör Abstract: Antiplatelet compounds interfere with the platelet activation cascade at different levels. The antiplatelet effect of the thienopyridine, clopidogrel, results from antagonism of a platelet ADP receptor, P 2T, resulting in inhibition of platelet activation. This antagonism is non-competitive, irreversible, and results in a 50 70% inhibition of platelet fibrinogen binding. Additionally, clopidogrel may also antagonize the ADP-induced inhibition of adenylate cyclase, possibly resulting in an elevated platelet cyclic adenosine monophosphate level after stimulation by an appropriate agonist, such as prostacyclin. This spectrum of antiplatelet activities is different from that of aspirin. Further, clopidogrel is associated with a reduction in gastrointestinal hemorrhage, making it a valuable therapeutic alternative to aspirin in oral, long-term prevention of atherothrombotic vascular occlusion. Key words: ADP; atherosclerosis; clopidogrel; platelet; thrombosis Atherosclerosis and atherothrombosis Atherosclerosis is a chronic vascular disease that develops over years and may remain asymptomatic for long periods of time. 1 Morphologically, there is a progressive narrowing of the arterial lumen, eventually resulting in regional ischemia, such as transient ischemic attacks (TIA), effort angina, or intermittent claudication. Atherosclerotic vessels may potentially undergo a catastrophic event acute thrombotic occlusion with the corresponding clinical manifestations of myocardial infarction, sudden death, or ischemic cerebral infarction. Each of these life-threatening events are initiated by platelet-dependent thrombus formation, most commonly at the thrombogenic surface of an atherosclerotic plaque. Antiplatelet therapy is a symptomatic and effective approach 2 to preventing the consequences of endothelial dysfunction in atherosclerotic vascular disease, which could otherwise result in uncontrolled intravascular platelet activation. Pathophysiology of platelet-dependent thrombus formation Thrombus formation at a site of arterial vascular injury is initiated by the adhesion of resting platelets to the vessel wall. This response is mediated by the expression of platelet adhesion molecules, such as GpIb/IX and GpIIb/IIIa, which bind to von Willebrand factor and other components of the vascular subendothelium. 3 The binding of these adhesion molecules, along with other integrins, is regulated by accessibility of the subendothelial matrix, with its Institut für Pharmakologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany Address for correspondence: Karsten Schrör, Institut für Pharmakologie, Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, D-40225, Düsseldorf, Germany. adhesive surfaces, to circulating blood. 4 Soluble agonists, such as adenosine diphosphate (ADP) and thromboxane A 2 (TxA 2 ) synergistically accelerate platelet activation. This results in platelet shape change, granule secretion, 5 and exposure of platelet phospholipids to circulating blood, which accelerates local thrombin formation. Finally, the platelet integrin, GpIIb/IIIa, is activated, undergoing a conformational change at the surface of the platelet allowing it to bind soluble fibrinogen. This results in the cross-linking of platelets via fibrinogen bridges, termed platelet aggregation. The significance of ADP in platelet activation Almost 40 years ago, ADP was found to cause red blood cell-dependent sticking (adhesion) of platelets to glass. 6,7 Shortly after that, it was also observed that ADP could induce platelet-to-platelet adhesion (aggregation). This action was dependent on the presence of Ca ++ and fibrinogen. 8,9 Further, platelet-dependent hemostatic plug formation was inhibited in the presence of ADP-metabolizing enzymes. 10 Shear stress induced platelet activation is largely dependent on ADP 11 and is resistant to aspirin, 12 as is ADP-induced platelet activation in vivo, i.e. in the presence of physiological Ca ++ concentrations. These data and a number of follow-up studies led to the view that ADP is one of the most important mediators of platelet activation in vivo. 13 There are several rich sources of extracellular nucleotides in the blood, such as ADP. These include red blood cells, endothelial cells and platelet-dense granules In the platelet aggregates formed after vascular injury, local extracellular nucleotide concentrations may temporarily exceed 100 M. 17 Thus, ADP appears to be a potent, broad-spectrum, endogenous platelet-stimulatory agent in vivo. Arnold X(98)VM244MP
2 248 K Schrör Mechanisms of ADP-induced platelet activation ADP receptor(s) Biochemical and pharmacologic findings suggest the existence of at least two different ADP receptors on the platelet membrane belonging to the P 2X1 and P 2T subtypes of purinergic receptors (Figure 1). The P 2X1 receptor is an ADP ligand associated with an ion channel. The P 2T receptor is a heptahelical membrane receptor that is coupled to intracellular signaling pathways via G-proteins. The P 2T receptor subtype mediates other, still unknown platelet-stimulating actions of ADP. There are about ADP receptors per platelet, a number comparable with those of other G-protein coupled platelet receptors, including vasopressin, -agonists and TxA ADP receptor signal transduction There are at least three different signal transduction pathways that may become activated after ligand binding to the platelet ADP receptor: activation of GpIIb/IIIa; inhibition of adenylate cyclase activation; and stimulation of phospholipase C (PLC ). The significance of an ADP-stimulated increase in cytosolic Ca ++ concentration via activation of PLC and the subsequent formation of inositol triphosphate and release of Ca ++ from intracellular storage sites has not been fully elucidated. 19 It has been shown, however, that increases in cytosolic Ca ++ levels are a consequence of PLC stimulation by TxA 2. Inhibition of TxA 2 formation by aspirin may enhance the antiaggregatory nature of ADP antagonists on platelets via this mechanism (Figure 1). The most important cellular signal transduction pathway of ADP, however, may result from activation of the platelet GpIIb/IIIa complex, the final common pathway of platelet aggregation used by all platelet agonists. Irreversible platelet aggregation requires the binding of fibrinogen to this receptor. As with other agonists, such as collagen and thrombin, ADP initiates the activation of fibrinogen binding sites on platelet membranes. This occurs via conformational changes in the GpIIb/IIIa complex that are prerequisite to stable platelet thrombus formation. Mode of action of clopidogrel Although most evidence suggests that the activity of clopidogrel is a direct result of its antagonism of the ADP receptor, it may also interfere with a more distal step in the platelet activation pathway, such as a -protein response or tyrosine kinase phosphorylation. 20 This mode of action is different from aspirin, which does not directly affect ADPinduced platelet functions, including platelet adhesion and -granule secretion. In contrast to aspirin, clopidogrel does not directly interfere with arachidonic acid metabolism. Thus, the inhibition of platelet aggregation brought about by clopidogrel is completely different from that of aspirin. Figure 1 Signal transduction by ADP in platelets and its modification by clopidogrel. (Abbreviations: ADP, adenosine diphosphate; P 2X1, principal platelet ADP receptor (ADP-liganded ionic channel); AC, adenylate cyclase; camp, cyclic adenosine monophosphate; IP 3, inositol triphosphate; DAG, diacylglycerol; PLC, phospholipase C; Ca ++, calcium; PIP 2, phosphatidylinositol 4,5-bisphosphate; TP, thromboxane receptor; IP, prostacyclin receptor; TxA 2, thromboxane A 2 ;G q,g s,g i,g proteins; P 2T, purinergic platelet ADP receptor (high-affinity, G-protein-coupled heptahelical receptor); GP IIb/IIIa, glycoprotein IIb/IIIa; ATP, adenosine triphosphate; PGI 2, prostacyclin.)
3 Pharmacology of clopidogrel 249 ADP receptors Clopidogrel markedly reduces high-affinity ADP binding to a subset of ADP receptors (P 2T ) at the platelet membrane (Figure 1). 21,22 The affinity of these receptors for ADP remains unchanged during treatment with clopidogrel, which causes a 60 70% reduction in ADP binding. 18,22 A similar, 70% reduction in ADP binding was observed in one patient with a congenitally defective ADP response (Figure 2). 21 Clopidogrel s inhibition of ADP binding is non-competitive and irreversible, 23 although 20 30% of receptors are not affected. Since clopidogrel does not affect the shape change associated with platelet activation, it has been suggested that the population of binding sites that remain unaffected after treatment might be specifically involved in the platelet shape change. 23 It has also been suggested that clopidogrel has effects other than on platelets, such as the modulation of vascular tone. 24 GpIIb/IIIa complex As a consequence of reduced agonist binding at the P 2T ADP receptor, there is a marked inhibition of ADP-induced conformational changes in the GpIIb/IIIa complex. This activation is essential for the binding of soluble agonists, such as fibrinogen, and subsequent platelet aggregate formation. 20,25 Insufficient fibrinogen bridging resulting from reduced numbers of platelet GpIIb/IIIa receptors will also result in less stable platelet aggregates and more rapid clot resolution. 25 Fibrinogen binding after clopidogrel treatment is reduced by about 70%. 25 The clinical result is a doubling of the bleeding time. In contrast with ADP receptor antagonists, selective GpIIb/IIIa antagonists, such as abciximab, integrelin and tirofiban, bind directly to the integrin and prevent the access of ligands, such as soluble fibrinogen, to the activated GpIIb/IIIa complex through competitive antagonism. Platelet secretion Studies in non-anticoagulated, ex vivo human blood have shown that clopidogrel profoundly inhibits both the Figure 2 ADP binding sites in human platelets after oral clopidogrel (75 mg/day) compared with a patient with a congenital defect in ADP response. ADP binding was determined with the stable ligand 2MeS-ADP. (Source: data from refs 21 and 22.) degranulation of platelets in contact with a collagen surface and the subsequent formation of a thrombus. Since clopidogrel reduces fibrin deposition and thrombus formation, it has been suggested that clopidogrel interferes with plateletto-platelet interactions 26 through its effects on ADP-dependent platelet activation. Adenylate cyclase activity Exposure of platelets to ADP causes inhibition of adenylate cyclase at the platelet membrane. 27 Clopidogrel suppresses this inhibition of adenylate cyclase and the subsequent fall in camp levels. 28,29 This action might be less significant in ex vivo conditions because of the short half-life of compounds that increase camp levels such as prostacyclin (PGI 2 ). However, this response may contribute to clopidogrel s inhibition of platelet aggregation in vivo, particularly in ischemic areas, where PGI 2 production is increased. 30 Active principle(s) of clopidogrel Clopidogrel is inactive in vitro in conventional assays of platelet activation. Ex vivo data suggest that the irreversible inhibition of platelet aggregation by clopidogrel is not mediated by metabolites detected in the plasma. More detailed studies of the mechanisms involved in clopidogrel bioactivation were conducted in animals, particularly the rat. In this species, the antiaggregating potency of clopidogrel was similar after intravenous or oral administration, but was markedly reduced after functional hepatectomy. 31 It was also seen that inhibition of cytochrome P 450 (CYP) by drugs or antibodies decreased the antiaggregating effect of clopidogrel, while stimulators of the CYP1A1 enzyme subfamily had the opposite effect. 23 Based on these data, it was suggested that the active principle of clopidogrel is generated in the liver by an unknown metabolic change that activates the native drug. 31 Time-dependency of antiplatelet action Clinical inhibition of platelet aggregation does not occur immediately with administration of clopidogrel. A detectable antiplatelet effect can be observed within 2 h of treatment; 32 it becomes significant after 2 days of treatment and maximum inhibition is achieved after 4 7 days. 33 The velocity of the initial response may be increased with higher doses. 32 Interestingly, one preliminary report has suggested that administration of a loading dose of clopidogrel (375 mg) will result in a 55% inhibition of ADP-induced platelet aggregation after 1 h and 80% inhibition after 5 h. A maximal prolongation of bleeding time approximately twofold was seen after 3 days. 34 The half-life of clopidogrel (assessed with the metabolite SR 26334) is 7 8 h after a single administration; full recovery of platelet activity is seen about 1 week after treatment is ended. This suggests normalization of platelet function through platelet turnover. 21,33,35 The efficacy of clopidogrel (75 mg/day) was comparable with that of ticlopidine (500 mg/day). 36 The ability of clopidogrel to inhibit platelet function and prolong bleeding time was unchanged between weeks 1 and 4 of treatment. 36 A study in healthy volunteers found that the antiplatelet effects of clopidogrel (75 mg/day) increased by less than 10% after 3 months of therapy, compared with
4 250 K Schrör the level of steady-state inhibition achieved after 8 12 days of therapy. There was no further prolongation of the bleeding time. Similarly, no significant differences in antiplatelet efficacy were seen when clopidogrel was administered to young and elderly patients with and without atherosclerosis. 37 Collectively, these data suggest that the prolonged half-life of clopidogrel after regular daily intake for several weeks does not result in a potentiation of antiplatelet effects or additional prolongation of bleeding time. Clopidogrel versus aspirin In dose-ranging studies, clopidogrel (75 mg) was found to have the same effect as ticlopidine (500 mg). 36 The clinical efficacy of clopidogrel has been demonstrated in the CAP- RIE trial 38 in which clopidogrel (75 mg/day) was found to cause a significant 8.7% relative risk reduction (p = 0.043) in the combined vascular endpoints of myocardial infarction, ischemic stroke and vascular death compared with aspirin (350 mg/day). The mean duration of treatment was about 2 years. The percentage of patients who dropped out of the study early because of adverse events was 11.4%: 6.01% of these came from the aspirin group and 5.38% came from the clopidogrel group. 38 Not surprisingly, the side-effects associated with aspirin and clopidogrel were different. The most common side-effects observed during clopidogrel therapy were diarrhea and rash. Upper gastrointestinal discomfort and bleeding occurred more frequently during aspirin therapy. Importantly, the CAPRIE trial showed that the rate of neutropenia was similar in both groups. Because of the different potencies, mechanisms of action and adverse effect spectra, clopidogrel is considered to be a valuable therapeutic alternative to aspirin. An interesting approach to antiplatelet therapy is the combined use of clopidogrel and aspirin for prevention of thromboembolic stent occlusion. Several controlled clinical trials have indicated that the combined use of ticlopidine and aspirin is more effective and has fewer side-effects than conventional therapy with anticoagulants. 39 Similar beneficial results were obtained in patients who received stents as a bail-out procedure for failed angioplasty or suboptimal PTCA results. 40 However, to date these uses have not been studied with clopidogrel in humans. Animal experiments clearly suggest that clopidogrel prevents thrombotic reocclusion of coronary, 41 femoral, 41,42 and carotid arteries after endothelial injury under conditions in which aspirin is ineffective. In addition, clopidogrel prevented coronary artery reocclusion more effectively than aspirin. 43 Clopidogrel pharmacology Drug interactions Data in animal experiments (rats) suggest that clopidogrel might interact with at least two components of the hepatic P 450 system. Therefore, it is important to know whether similar events occur in humans, since this could eventually prolong the drug s half-life. Alternatively, ADP receptor antagonists may interfere with the metabolism of other compounds that are subject to extensive hepatic clearance, such as phenytoin, theophylline and antipyrin. To examine the potential in vivo inhibition and/or induction of hepatic enzymes, clopidogrel use was studied in healthy male volunteers. After clopidogrel administration (75 mg/day for 10 days), no statistically significant difference in the elimination half-life of antipyrine (non-specific isoenzyme substrate) was observed. Plasma levels of gamma-glutamyl transpeptidase ( -GT) and cortisol were not affected by this treatment, nor was urinary excretion of 6- OH-cortisol (CYP3A substrate). This led the authors to conclude that clopidogrel, under the conditions of this study, does not cause hepatic enzyme induction nor does it modify the activity of hepatic oxidative enzyme systems. 44 No liver dysfunction was reported in the CAPRIE trial. 38 It should be noted, however, that the CAPRIE trial was a phase III study with numerous exclusionary criteria for patient selection, including a history of drug-induced hepatic abnormalities. Other studies have indicated that pharmacologic interactions do not occur during co-administration of clopidogrel and aspirin, 45 digoxin, 46 heparin, 47 atenolol, 48 or nifedipine. 48 The results of studies performed with clopidogrel show that it has antiplatelet activity and reduces the occurrence of thrombotic occlusive vascular disease. Clopidogrel has a greater efficacy than aspirin (8.7% relative risk reduction compared with aspirin; p = 0.043), the current gold standard for antiplatelet activity, and a reduced association with gastrointestinal bleeding and discomfort; in addition, clopidogrel does not appear to cause neutropenia. Based on results of the CAPRIE trial, clopidogrel appears to be an efficacious and safe new agent for patients at risk of occlusive vascular events. Note added in proof Subsequent to the original submission of this paper, Weber and co-workers 49 have reported that clopidogrel specifically inhibits ADP-induced aggregation of washed human platelets in vitro without hepatic bioactivation. References 1 Ross R, Fuster V. The pathogenesis of atherosclerosis. In: Fuster V, Ross R, Topol EJ eds. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven, 1996: Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: Ruggeri ZM. Mechanisms initiating platelet thrombus formation. Thromb Haemost 1997; 78: Du X, Ginsberg MH. Integrin IIb 3 and platelet function. Thromb Haemost 1997; 78: Schafer AL. Antiplatelet therapy. Am J Med 1996; 101: Hellem A. The adhesiveness of human blood platelets in vitro. Scand J Clin Invest 1960; 12: Gaarder A, Jonsen J, Laaland S, Hellem A, Owren PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: Born GVR. Platelet aggregation and its reversal. Nature 1962; 194: O Brien JR. Platelet aggregation. Part II. Some results from a new method of study. J Clin Pathol 1962; 15: Zawilska KM, Born GVR, Begent N. Effect of ADP-utilizing enzymes on the arterial bleeding time in rats and rabbits. Br J Haematol 1982; 50:
5 Pharmacology of clopidogrel Moritz MW, Reimers RC, Baker RK, Sutera SP, Joist JH. Role of cytoplasmic and releasable ADP in platelet aggregation induced by laminar shear stress. J Lab Clin Med 1983; 101: Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Hellums JD. Shear-induced platelet aggregation can be mediated by vwf released from platelets, as well as by exogenous large or unusually large vwf multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988; 71: Born GVR. Adenosine diphosphate is a mediator of platelet aggregation in vivo: an editorial view. Circulation 1985; 72: Rao AK, Willis J, Holmsen H. A major role of ADP in thromboxane transfer experiments: studies in patients with platelet secretion defects. J Lab Clin Med 1984; 104: Valles J, Santos MT, Aznar J et al. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release and recruitment. Blood 1991; 78: Santos MT, Valles J, Marcus AJ et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes: a new approach to platelet activation and recruitment. J Clin Invest 1991; 87: Coade SB, Pearson JD. Metabolism of adenine nucleotides in human blood. Circ Res 1989; 65: Mills DC. ADP receptors on platelets. Thromb Haemost 1996; 76: Gachet C, Hechler B, Léon C, Vial C, Ohlmann P, Cazenave J-P. Purinergic receptors on blood platelets. Platelets 1996; 7: Nurden AT. New thoughts on strategies for modulating platelet function through the inhibition of surface receptors. Haemostasis 1996; 26 (suppl 4): Mills DCB, Puri RN, Hu CJ et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992; 12: Gachet C, Cattaneo M, Ohlmann PO et al. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol 1995; 91: Savi P, Combalbert J, Graich C et al. The antiaggregating activity of clopidogrel is due to metabolic activation by the hepatic cytochrome P450 1A. Thromb Haemost 1994; 72: Yang LH, Fareed J. Vasomodulatory action of clopidogrel and ticlopidine. Thromb Res 1997; 86: Humbert M, Nurden P, Bihour C et al. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol 1996; 16: Roald HE, Barstad M, Kierulf P et al. Clopidogrel a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions. Thromb Haemost 1994; 71: Cooper DMF, Rodbell M. ADP is a potent inhibitor of human platelet plasma membrane adenylate cyclase. Nature 1979; 282: Gachet C, Stierle A, Cazenave JP et al. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb/IIIa complex in rat and man. Biochem Pharmacol 1990; 40: Defreyn G, Gachet C, Savi P, Driot F, Cazenave JP, Maffrand JP. Ticlopidine and clopidogrel [SR 25990C] selectively neutralize ADP inhibition of PGE 1 -activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost 1991; 65: Schrör K. The basic pharmacology of ticlopidine and clopidogrel. Platelets 1993; 4: Savi P, Herbert J-M, Pflieger AM et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992; 44: Kieffer G, Caplain H, Thiercelin JF, Thebault JJ. Tolerance and pharmacological activity of a new antiplatelet agent clopidogrel [SR C] in normal healthy volunteers after single increasing administrations. Thromb Haemost 1989; 62: 411 [abstract]. 33 Caplain H, Kieffer G, Thiercelin JF, Thebault JJ. Tolerance and clinical pharmacology of repeated administration of clopidogrel [SR C], a new antiplatelet agent, at three dose levels in normal healthy volunteers. Thromb Haemost 1989; 62: 410 [abstract]. 34 Bachmann F, Savcic M, Hauert J, Geudelin B, Kieffer G, Cariou R. Rapid onset of inhibition of ADP-induced platelet aggregation by a loading dose of clopidogrel. Eur Heart J 1996; 17 (suppl): Herbért JM, Frekel D, Vallee E et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11: Boneu B, Destelle G on behalf of the Study Group. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996; 76: Guillin M-C, Bonnet G, Sissmann J, Neccian J, Dickinson JP. Pharmacodynamics and pharmacokinetics of the novel antiplatelet agent, clopidogrel, in the young and the elderly with and without symptomatic atherosclerosis. Eur Heart J 1996; 17 (suppl): Gent M, CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events [CAPRIE]. Lancet 1996; 348: Schömig A, Neumann F-J, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: Lablanche J-M, McFadden EP, Bonnet J-L et al. Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach on intracoronary stent management. Eur Heart J 1996; 17: Yao S-K, Ober JC, McNatt J et al. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res 1992; 70: Samama CM, Bonnin P, Bonneau M et al. Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig. Thromb Haemost 1992; 68: Yao S-K, Ober JC, Ferguson JJ et al. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 1994; 267: H488-H Pierce CH, Houle J-M, Kieffer G, Dickinson JP. Absence of effect of clopidogrel on human hepatic P-450 activities. Eur Heart J 1996; 17 (suppl): 160 [abstract]. 45 Caplain H, D Honneur G, Cariou R. Lack of interaction of aspirin (100 mg) with chronic clopidogrel in volunteers. Haemostasis 1996; 26 (suppl 3): Peeters PAM, Crijns WJ, Tamminga WJ et al. Absence of pharmacokinetic interaction between the novel antiplatelet agent, clopidogrel, and digoxin. Eur Heart J 1996; 17 (suppl): 160 [abstract]. 47 D Honneur G, Caplain H, Cariou R, Brouard R. Interaction study between clopidogrel and prolonged intravenous heparin administration in young healthy volunteers. Haemostasis 1996; 26 (suppl 3): Forbes CD, Belch JJ, Bridges AB et al. Pharmacodynamic compatability of clopidogrel with atenolol and nifedipine co-medication in patients with atherosclerotic disease. Eur Heart J 1996; 17 (suppl): 160 [abstract]. 49 Weber A-A, Reimann S, Schrör K. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro. Br J Pharmacol 1998 (in press).
Clopidogrel with Aspirin Is the Optimal Antiplatelet Regimen for Intracoronary Stenting
Clopidogrel Aspirin Steinhubl for and Stenting Topol Journal of Thrombosis and Thrombolysis 1999;7:227 231 Kluwer Academic Publishers. Boston. Printed in the Netherlands. Clopidogrel with Aspirin Is the
More informationAntiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationOral Anticoagulant Drugs
Oral Anticoagulant Drugs Spoiled sweet clover caused hemorrhage in cattle(1930s). Substance identified as bishydroxycoumarin. Initially used as rodenticides, still very effective, more than strychnine.
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More information- Mohammad Sinnokrot. -Ensherah Mokheemer. - Malik Al-Zohlof. 1 P a g e
-1 - Mohammad Sinnokrot -Ensherah Mokheemer - Malik Al-Zohlof 1 P a g e Introduction Two of the most important problems you will face as a doctor are coagulation and bleeding, normally they are in balance,
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationLOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING
LOW DOSE ASPIRIN FOR PROPHYLAXIS OF CARDIOVASCULAR DISEASE FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING Use of Low Dose Aspirin to Treat and Prevent Cardiovascular Disease In recent decades, aspirin
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More informationLa Trombosi Arteriosa
La Trombosi Arteriosa Prof. Giovanni Davì Medicina Interna Chieti Platelet activation and thrombosis Harrison 19 edizione Platelets are essential for primary hemostasis and repair of the endothelium They
More informationAntiplatelet activity and the use of Cilostazol in Symptomatic ICAS Ameer E. Hassan DO
Antiplatelet activity and the use of Cilostazol in Symptomatic ICAS Ameer E. Hassan DO Assistant Professor of Neurology, Radiology, and Neurosurgery University of Texas Health Science Center - San Antonio
More informationCentral role of the P2Y 12 receptor in platelet activation
SPOTLIGHT Central role of the P2Y 12 receptor in platelet activation Robert T. Dorsam 1,2 and Satya P. Kunapuli 1,2,3 1 Department of Pharmacology, 2 Sol Sherry Thrombosis Research Center, and 3 Department
More informationHemostasis and Thrombosis
Hemostasis Hemostasis and Thrombosis Normal hemostasis is a consequence of tightly regulated processes that maintain blood in a fluid state in normal vessels, yet also permit the rapid formation of a hemostatic
More informationPlatelet function testing in cardiovascular diseases
Hematology, 2005; 10 Supplement 1: 132 /137 PLATELET DISORDERS Platelet function testing in cardiovascular diseases ALAN D. MICHELSON From the Center for Platelet Function Studies, Departments of Pediatrics,
More informationΔοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Εμμανουήλ Βαβουρανάκης
Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Εμμανουήλ Βαβουρανάκης Αναπλ. Καθηγητής Καρδιολογίας Ιπποκράτειο ΓΝΑ Haematology Research Laboratory!! Platelets Small anucleate discoid cells Involved
More informationAnticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT
Haemostasis Thrombosis Phases Endogenous anticoagulants Stopping blood loss Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Vascular Platelet
More informationIMMATURE PLATELETS CLINICAL USE
HAEMATOLOGY FEBRUARY 217 WHITE PAPER IMMATURE PLATELETS CLINICAL USE Identifying poor antiplatelet drug response and its risks early on Platelets are important cells for repairing endothelial lesions,
More informationThe thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments
REVIEW ARTICLE The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments P. C. A. Kam 1 and C. M. Nethery 2 1 Professor of Anaesthesia,
More informationEDUCATIONAL COMMENTARY PLATELET DISORDERS
EDUCATIONAL COMMENTARY PLATELET DISORDERS Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Earn
More informationPlatelets and new antiplatelet drugs
REVIEW Platelets and new antiplatelet drugs Rosemarie A Reiter & Bernd Jilma Author for correspondence Medical University of Vienna, Department of Clinical Pharmacology, Währinger Gürtel 18 20, A-1090
More informationDo We Need Platelet Function Assays?
Do We Need Platelet Function Assays? Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA The Antiplatelet Effect of Clopidogrel Varies Widely Among Individuals
More informationCoronary thrombosis is a fundamental event in the pathophysiology of atherosclerotic coronary
Coronary disease ANTIPLATELET TREATMENT IN STABLE CORONARY ARTERY DISEASE c PLATELETS Correspondence to: Dr Charles C Knight, London Chest Hospital, Bonner Road, London E2 9JX, UK; knightlch@aol.com Charles
More informationCase presentation 1: Mr F. is a
CLINICIAN UPDATE Platelet Function Testing in Cardiovascular Diseases Alan D. Michelson, MD Case presentation 1: Mr F. is a 60-year-old man with unstable angina who takes aspirin, 81 mg/day. A platelet
More informationHemostasis. Learning objectives Dr. Mária Dux. Components: blood vessel wall thrombocytes (platelets) plasma proteins
Hemostasis Learning objectives 14-16 Dr. Mária Dux Components: blood vessel wall thrombocytes (platelets) plasma proteins Hemostatic balance! procoagulating activity anticoagulating activity 1 Thrombocytes
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationAnti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib!
Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib! Roxana Mehran, MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Research support
More informationPhysiology Unit 1 CELL SIGNALING: CHEMICAL MESSENGERS AND SIGNAL TRANSDUCTION PATHWAYS
Physiology Unit 1 CELL SIGNALING: CHEMICAL MESSENGERS AND SIGNAL TRANSDUCTION PATHWAYS In Physiology Today Cell Communication Homeostatic mechanisms maintain a normal balance of the body s internal environment
More informationThrombosis. Jeffrey Jhang, M.D.
Thrombosis Jeffrey Jhang, M.D. Introduction The human hemostatic system has evolved to maintain blood flow under normal physiologic conditions while remaining primed to rapidly respond to vascular injury
More informationHemostasis Haemostasis means prevention of blood loss from blood vessels.
١ Hemostasis Haemostasis means prevention of blood loss from blood vessels. Bleeding is stopped by several mechanisms, which are: 1. Local vasoconstriction 2. Formation of platelet plug 3. Blood coagulation
More informationArteriopatie periferiche. Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante
Arteriopatie periferiche Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante Anna Falanga USC Immunoematologia e Medicina Trasfusionale ASST Papa Giovanni XXIII, Bergamo Obiettivi della
More informationPlatelets play an important role in primary hemostasis via
Role of ADP Receptor P2Y 12 in Platelet Adhesion and Thrombus Formation in Flowing Blood Jasper A. Remijn, Ya-Ping Wu, Ellen H. Jeninga, Martin J.W. IJsseldijk, Gijsbert van Willigen, Philip G. de Groot,
More informationPHM142 Lecture 4: Platelets + Endothelial Cells
PHM142 Lecture 4: Platelets + Endothelial Cells 1 Hematopoiesis 2 Platelets Critical in clotting - activated by subendothelial matrix proteins (e.g. collagen, fibronectin, von Willebrand factor) and thrombin
More informationDrug Receptor Interactions and Pharmacodynamics
Drug Receptor Interactions and Pharmacodynamics Dr. Raz Mohammed MSc Pharmacology School of Pharmacy 22.10.2017 Lec 6 Pharmacodynamics definition Pharmacodynamics describes the actions of a drug on the
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationConflicts of interest. Very balanced Lilly and team, AZ and BMS
Conflicts of interest Very balanced Lilly and team, AZ and BMS Distal microcirculation receives platelet microparticles Release TxA 2 and plugs microcapillaries Healthy vascular endothelium Prevents (antithrombotic
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationIndex. Hematol Oncol Clin N Am 19 (2005) Note: Page numbers of article titles are in boldface type.
Hematol Oncol Clin N Am 19 (2005) 203 208 Index Note: Page numbers of article titles are in boldface type. A Abciximab, as an antiplatelet agent, 93 94 Acute coronary syndromes, use of antiplatelet drugs
More informationHemostasis Haemostasis means prevention of blood loss from blood vessels.
1 Hemostasis Haemostasis means prevention of blood loss from blood vessels. Bleeding is stopped by several mechanisms, which are: 1. Local vasoconstriction 2. Formation of platelet plug 3. Blood coagulation
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationAcute coronary syndromes
Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.
More informationPropagation of the Signal
OpenStax-CNX module: m44452 1 Propagation of the Signal OpenStax College This work is produced by OpenStax-CNX and licensed under the Creative Commons Attribution License 3.0 By the end of this section,
More informationHemodynamic Disorders, Thrombosis, and Shock. Richard A. McPherson, M.D.
Hemodynamic Disorders, Thrombosis, and Shock Richard A. McPherson, M.D. Edema The accumulation of abnormal amounts of fluid in intercellular spaces of body cavities. Inflammation and release of mediators
More informationJournal of the American College of Cardiology Vol. 50, No. 19, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 50, No. 19, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.07.058
More informationPrasugrel: Son of Clopidogrel or Distant Cousin? Disclosures. Objectives
Prasugrel: Son of Clopidogrel or Distant Cousin? By John J. Bon, Pharm.D., BCPS Lead Clinical Pharmacist, Critical Care Summa Health System Disclosures I have no actual or potential conflict of interest
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationThrombosis Research active studies
Thrombosis Research active studies A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility
More informationLecture Outline. Hormones & Chemical Signaling. Communication Basics: Overview. Communication Basics: Methods. Four methods of cell communication
Lecture Outline Hormones & Chemical Signaling Communication Basics Communication Overview Communication Methods Signal pathways Regulation (modulation) of signal pathways Homeostasis... again Endocrine
More informationT he leading cause of morbidity and mortality
155 CARDIOLOGY UPDATE Antiplatelet therapy in cardiovascular disease M W H Behan, R F Storey... Platelet activation and aggregation are considered to be central to arterial thrombus formation. Antiplatelet
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 8, 2014 Theodore A Bass, MD FSCAI Immediate Past-President SCAI Professor of Medicine, University of Florida Medical Director UF Health CV
More informationCh. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma
Chapt. 45 Ch. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma Inheritance of X-linked gene for Factor VIII hemophilia A Explain the
More informationReceptors and Drug Action. Dr. Subasini Pharmacology Department Ishik University, Erbil
Receptors and Drug Action Dr. Subasini Pharmacology Department Ishik University, Erbil Receptors and Drug Action Receptor Receptor is defined as a macromolecule or binding site located on the surface or
More informationClinical Aspects of Platelet Inhibitors and Thrombus Formation Telly A. Meadows and Deepak L. Bhatt. doi: /01.RES
Clinical Aspects of Platelet Inhibitors and Thrombus Formation Telly A. Meadows and Deepak L. Bhatt Circ Res. 2007;100:1261-1275 doi: 10.1161/01.RES.0000264509.36234.51 Circulation Research is published
More informationDr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre
Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationThis slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion
This slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion Topics of today lectures: Hemostasis Meaning of hemostasis Mechanisms
More informationHEART HEALTH WEEK 2 SUPPLEMENT. A Beginner s Guide to Cardiovascular Disease ATHEROSCLEROSIS. Fatty deposits can narrow and harden the artery
WEEK 2 SUPPLEMENT HEART HEALTH A Beginner s Guide to Cardiovascular Disease ATHEROSCLEROSIS FIGURE 1 Atherosclerosis is an inflammatory process where cholesterol is deposited in the wall of arteries and
More informationin the secondary preve
12 PRACTICAL NEUROLOGY Antiplatelet drugs in the secondary preve Pract Neurol: first published as 10.1046/j.1474-7766.2002.00303.x on 1 February 2002. Downloaded from http://pn.bmj.com/ INTRODUCTION Stroke
More informationNOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS
Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept
More informationProf. Jindřich Špinar, MD
Prof. Jindřich Špinar, MD Head of the Internal Cardiology dpt., University Hospital Brno Focuses on clinical cardiology, acute and chronic heart failure, ischemic heart gisease, hypertension Vice head
More informationEvaluation of Clopidogrel Resistance. in ischemic stroke patients.
ORIGINAL ARTICLE Evaluation of Clopidogrel Resistance in Ischemic Stroke Patients Takuya Fukuoka, Daisuke Furuya, Hidetaka Takeda, Tomohisa Dembo, Harumitu Nagoya, Yuji Kato, Ichiro Deguchi, Hajime Maruyama,
More informationPrevenzione secondaria dell ischemia cerebrale di origine arteriosa. Marco Cattaneo. Ospedale San Paolo Università degli Studi di Milano
Prevenzione secondaria dell ischemia cerebrale di origine arteriosa Marco Cattaneo Ospedale San Paolo Università degli Studi di Milano Cerebral Ischemia of Arterial Origin (CIAO) Cumulative meta-analysis
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationCoagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU
Coagulation Disorders Dr. Muhammad Shamim Assistant Professor, BMU 1 Introduction Local Vs. General Hematoma & Joint bleed Coagulation Skin/Mucosal Petechiae & Purpura PLT wound / surgical bleeding Immediate
More informationAgents for Peripheral Vascular Disease & Thrombosis
Agents for Peripheral Vascular Disease & Thrombosis Edward JN Ishac, Ph.D. Smith Building, Room 742 eishac@vcu.edu 828-2127 Department of Pharmacology and Toxicology Medical College of Virginia Campus
More informationAgents for Peripheral Vascular Disease & Thrombosis
Agents for Peripheral Vascular Disease & Thrombosis Edward JN Ishac, Ph.D. Smith Building, Room 742 eishac@vcu.edu 828-2127 Department of Pharmacology and Toxicology Medical College of Virginia Campus
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationOutline Anti-coagulant and anti-thrombotic drugs Haemostasis and Thrombosis Year 3 Dentistry
Outline Anti-coagulant and anti-thrombotic drugs Year 3 Dentistry Professor Yotis Senis Cellular Haemostasis y.senis@bham.ac.uk I. Haemostasis and II. Coagulation and anti-coagulants III. Platelets and
More information( Aspirin ) ( Stroke ) ( Dosage ) ( Diabetes ) ( Metabolic syndrome ) ( Primary prevention ) Aspirin Aspirin Aspirin. Aspirin.
2007 18 1-10 ( 75 150 mg/day ) ( American Heart Association AHA ) ( American Diabetes Association ADA ) 75 150 mg/day ( ) ( ) ( Stroke ) ( Dosage ) ( Diabetes ) ( Metabolic syndrome ) ( Primary prevention
More informationASPIRIN AND VASCULAR DISEASE
ASPIRIN AND VASCULAR DISEASE SUMMARY Aspirin is an effective antiplatelet agent for patients with cardiovascular and cerebrovascular disease. Incidence of adverse effects and drug interactions increases
More informationQuinn Capers, IV, MD
Heart Attacks Mended Hearts Presentation, January, 2017 Quinn Capers, IV, MD Associate Professor of Medicine (Cardiovascular Medicine) Director, Transradial Coronary Interventions Division of Cardiovascular
More informationDRUGS USED IN COAGULATION DISORDERS
DRUGS USED IN COAGULATION DISORDERS Course: Integrated Therapeutics 1 Lecturer: Dr. E. Konorev Date: November 1, 2010 Materials on: Exam #6 Required reading: Katzung, Chapter 34 1 DISORDERS OF COAGULATION
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationAnnals of RSCB Vol. XVI, Issue 1
THE STUDY OF PROTHROBOTIC STATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES Oana Bădulescu 1, Codruţa Bădescu 2, Manuela Ciocoiu 1, Magda Bădescu 1 1 DEPARTMENT OF PATHOPHYSIOLOGY;
More informationPHRM20001 NOTES PART 1 Lecture 1 History of Pharmacology- Key Principles
PHRM20001 NOTES PART 1 Lecture 1 History of Pharmacology- Key Principles Hippocrates (5 th century BCE):... benefit my patients according to my greatest ability and judgment, and I will do no harm or injustice
More informationLipids and Membranes
Lipids and Membranes Presented by Dr. Mohammad Saadeh The requirements for the Pharmaceutical Biochemistry I Philadelphia University Faculty of pharmacy Membrane transport D. Endocytosis and Exocytosis
More informationIschemic heart disease
Ischemic heart disease Introduction In > 90% of cases: the cause is: reduced coronary blood flow secondary to: obstructive atherosclerotic vascular disease so most of the time it is called: coronary artery
More informationAntiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Franz-Josef Neumann Herz-Zentrum Bad Krozingen Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
More informationNew Topics in Aspirin Therapy
Aspirin Therapy New Topics in Aspirin Therapy JMAJ 47(12): 566 572, 2004 Makoto HANDA Director and Associate Professor, Department of Transfusion Medicine and Cell Therapy, School of Medicine, Keio University
More informationSymptomatic carotid stenosis is associated with a markedly
Switching off Embolization From Symptomatic Carotid Plaque Using S-Nitrosoglutathione Zoltan Kaposzta, MD; John F. Martin, F Med Sci; Hugh S. Markus, FRCP Background Current antiplatelet regimens fail
More informationSTUDIES OF PLATELET FUNCTION, AND EFFECTS OF ASPIRIN AND CLOPIDOGREL TREATMENT
From the Department of Medicine Solna, Clinical Pharmacology Unit, Karolinska Institutet, Stockholm, Sweden STUDIES OF PLATELET FUNCTION, AND EFFECTS OF ASPIRIN AND CLOPIDOGREL TREATMENT Christina Perneby,
More informationJournal of the American College of Cardiology Vol. 45, No. 9, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 45, No. 9, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.01.030
More informationCHAPTER-I MYOCARDIAL INFARCTION
CHAPTER-I MYOCARDIAL INFARCTION Definition A myocardial infarction, more commonly known as MI or acute myocardial infarction (AMI) or heart attack is a condition where there is interruption of blood supply
More informationPrasugrel a step ahead in antiplatelet therapy
Prasugrel a step ahead in antiplatelet therapy VS Srinath, MD (Med), DNB (Cardiology) The burden of atherosclerotic disease in the United States and across the world is vast. Although the symptoms of atherosclerosis
More informationPATHOPHYSIOLOGY OF ACUTE CORONARY SYNDROMES
PATHOPHYSIOLOGY OF ACUTE CORONARY SYNDROMES Brian R. Holroyd, MD, FACEP, FRCPC Professor and Director, Division of Emergency Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton,
More informationANTICOAGULANTS & FIBRINOLYTIC AGENTS Chapter 34
ANTICOAGULANTS & FIBRINOLYTIC AGENTS Chapter 34 Dr. Azadeh Mesripour (Ph.D) Pharm.MUI 2015 Dr. Mesripour 1 Platelet membrane receptors include the glycoprotein (GP) Ia receptor, binding to collagen (C);
More informationPart IV Antithrombotics, Anticoagulants and Fibrinolytics
Part IV Antithrombotics, Anticoagulants and Fibrinolytics "The meaning of good and bad, of better and worse, is simply helping or hurting" Emerson Chapter 16: Blood Coagulation and Fibrinolytic System
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationChapter 11. Cell Communication
Chapter 11 Cell Communication Overview: The Cellular Internet Cell-to-cell communication Is absolutely essential for multicellular organisms Concept 11.1: External signals are converted into responses
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationTirofiban (Aggrastat )
Cardiovascular Drug Reviews Vol. 17, No. 3, pp. 199 224 1999 Neva Press, Branford, Connecticut Tirofiban (Aggrastat ) Jacquelynn J. Cook, Bohumil Bednar, Joseph J. Lynch, Jr., Robert J. Gould, Melissa
More informationTopics of today lectures: Hemostasis
Topics of today lectures: Hemostasis Meaning of hemostasis Mechanisms of hemostasis - Vascular contraction - Platelets plug - Blood coagulation (clotting) - Structure and functions of platelets - Blood
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationAnticoagulation Update David J. Moliterno, MD
David J., MD Anticoagulant Agents n Cardiovascular Medicine: An Update David J., MD Professor and Chairman Division of Cardiovascular Medicine The University of Kentucky Linda and Jack Gill Heart nstitute
More informationClopidogrel and ASA after CABG for NSTEMI
Clopidogrel and ASA after CABG for NSTEMI May 17, 2007 Justin Lee Pharmacy Resident University Health Network Objectives At the end of this session, you should be able to: Explain the rationale for antiplatelet
More informationDyslipidemia Endothelial dysfunction Free radicals Immunologic
ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and
More informationVariability in Individual Responsiveness to Clopidogrel
Journal of the American College of Cardiology Vol. 49, No. 14, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.11.044
More informationHemostasis and Blood Forming Organs
Hemostasis and Blood Forming Organs Subcommittee: Williams, Patricia B. (Chair) pbwillia@umich.edu McMillan, David dcmcmillan@unmc.edu Dobrydneva, Yuliya dobrydy@evms.edu DEFEROXAMINE FERROUS SULFATE ferrous
More information